• N T de Siqueira Filha, M de Fatima Pessoa Militao de Albuquerque, R Legood, L Rodrigues, and A C Santos.
• London School of Hygiene and Tropical Medicine, UK. Electronic address: noemia.teixeira-filha@lshtm.ac.uk.
• Public Health. 2018 May 1; 158: 31-36.

ObjectiveThe objective of this study was to evaluate the direct and indirect costs of tuberculosis (TB) (active and latent TB [LTB]) and HIV co-infection from the patient perspective.Study DesignCosting study conducted alongside a pragmatic clinical trial.MethodsThe study was conducted in Brazil in a referral service for HIV/AIDS. We applied a standardised questionnaire to collect data about out-of-pocket expenses and indirect cost. The questionnaire was applied at every patient's appointment in the referral service after TB or LTB diagnosis. We followed all patients' pathways during the prediagnosis period and treatment period. For patients on sickness benefit due to TB/HIV, income loss was calculated as the difference between an employee's wages forgone and the sickness benefit received. The monetary value of the time loss was calculated based on the Brazilian minimum wage/2015.ResultsAmong 239 people living with HIV recruited in the first year of the trial, 31 patients were included into the costing study, 26 patients who were diagnosed and treated for TB/HIV and five patients who were diagnosed and treated for LTB/HIV. TB/HIV patients incurred higher total costs than LTB/HIV (US$ 1,429 vs US$ 166). The main cost component for TB/HIV was indirect costs, especially income loss (US$ 749).ConclusionsPublic health policies may address ways to prevent high patients' costs through the introduction of more accurate algorithms for TB diagnosis to prevent delays in the diagnosis and treatment.Copyright © 2017 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.

27 keywords...

hide…